文献速递肝病消化道肿瘤与早癌

东方肝胆外科医院/门静脉癌栓评分系统辅助肝细胞癌合并门静脉癌栓患者肝切除术决策:一项多中心研究

An Eastern Hepatobiliary Surgery Hospital/Portal Vein Tumor Thrombus Scoring System as an Aid to Decision Making on Hepatectomy for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: A Multicenter Study.
PubMed 文献 · Hepatology · 2019-03-12

该多中心研究建立了东方肝胆外科医院(EHBH)/门静脉癌栓(PVTT)评分系统,用于预测肝细胞癌(HCC)合并PVTT患者行R0肝切除术后的预后并指导患者选择。评分基于总胆红素、甲胎蛋白、肿瘤直径和卫星灶,在训练队列(432例)及前瞻性内部验证队列(285例)和三个外部验证队列(286、189、135例)中验证。评分≤/>3分两组中位总生存期分别为17.0个月 vs 7.9个月(P<0.001),预测准确性AUC为0.680-0.721,优于其他常用分期系统。

要点

  • EHBH-PVTT评分基于总胆红素、甲胎蛋白、肿瘤直径和卫星灶计算。
  • 评分≤3分与>3分患者中位总生存期分别为17.0个月 vs 7.9个月(P<0.001)。
  • 评分预测准确性AUC为0.680-0.721,优于其他常用HCC和PVTT分期系统。

核心结论

  • EHBH-PVTT评分系统在预测肝切除术后HCC合并PVTT患者预后方面比其他分期系统更准确。
  • 该评分系统可筛选出适合肝切除术的PVTT局限于门静脉主干一级分支或以上的HCC患者。
  • 该评分系统可作为其他HCC分期系统的补充。

研究设计与样本

  • 研究纳入以R0肝切除术作为初始治疗的PVTT局限于门静脉主干一级分支或以上的HCC患者。
  • EHBH-PVTT评分在训练队列中采用Cox回归模型建立,并在前瞻性内部验证队列和三个外部验证队列中验证。
  • 训练队列432例,前瞻性内部验证队列285例,三个外部验证队列分别为286例、189例和135例。

主要发现

  • EHBH-PVTT评分将患者分为≤3分和>3分两组,中位总生存期分别为17.0个月 vs 7.9个月(P<0.001)。
  • 评分预测准确性以时间依赖性受试者工作特征曲线下面积(AUC)衡量为0.680-0.721,高于其他常用HCC和PVTT分期系统。

关键数值与推荐

  • EHBH-PVTT评分≤3分与>3分两组中位总生存期分别为17.0个月 vs 7.9个月(P<0.001)。
  • 时间依赖性AUC为0.680-0.721,高于其他常用HCC和PVTT分期系统。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Portal vein tumor thrombus (PVTT) is a significant poor prognostic factor for hepatocellular carcinoma (HCC). Patients with PVTT limited to a first-order branch of the main portal vein (MPV) or above could benefit from negative margin (R0) liver resection (LR). An Eastern Hepatobiliary Surgery Hospital (EHBH)/PVTT scoring system was established to predict the prognosis of HCC patients with PVTT after R0 LR and guide selection of subgroups of patients that could benefit from LR. HCC patients with PVTT limited to a first-order branch of the MPV or above who underwent R0 LR as an initial therapy were included. The EHBH-PVTT score was developed from a retrospective cohort in the training cohort using a Cox regression model and validated in a prospective internal validation cohort and three external validation cohorts. There were 432 patients in the training cohort, 285 in the prospective internal validation cohort, and 286, 189, and 135 in three external validation cohorts, respectively. The score was calculated using total bilirubin, α-fetoprotein (AFP), tumor diameter, and satellite lesions. The EHBH-PVTT score differentiated two groups of patients (≤/>3 points) with distinct long-term prognoses (median overall survival [OS], 17.0 vs. 7.9 months; P < 0.001). Predictive accuracy, as determined by the area under the time-dependent receiver operating characteristic curves (AUCs; 0.680-0.721), was greater than that of the other commonly used staging systems for HCC and PVTT. Conclusion: The EHBH-PVTT scoring system was more accurate in predicting the prognosis of HCC patients with PVTT than other staging systems after LR. It selected appropriate HCC patients with PVTT limited to a first-order branch of the MPV or above for LR. It can be used to supplement the other HCC staging systems.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Zhang XP, Gao YZ, Chen ZH, et al. An Eastern Hepatobiliary Surgery Hospital/Portal Vein Tumor Thrombus Scoring System as an Aid to Decision Making on Hepatectomy for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: A Multicenter Study. Hepatology. 2019. PMID: 30586158. doi:10.1002/hep.30490

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。